Table 1.
Characteristics of identified clinical trials for Shakuyaku‐kanzo‐to
| Author (y) | Study design | Total n | Patients | Duration (wk) | Age (y) (mean ± SD) | Male (%) | Drug, dose | n | Outcomes | Adverse events |
|---|---|---|---|---|---|---|---|---|---|---|
| Kumada et al8 | Randomized double‐blind placebo‐controlled parallel study | 101 | Cirrhosis | 2 | 59.9 ± 8.4 | 40.4 | SKT 7.5 g/d | 52 | 67.30% | 14.30% |
| 2 | 60.3 ± 8.3 | 53.1 | Placebo | 49 | 36.70% | 4.90% | ||||
| Nishizawa et al9 | Randomized controlled trial | 75 | Cirrhosis | 12 | 62.7 ± 9.5 | 83.8 | SKT 50 mg/kg/d | 37 | 40.50% | 16.22% |
| 12 | 64.8 ± 10.3 | 81.6 | GJG 90 mg/kg/d | 38 | 60.50% | 0% | ||||
| Takao et al (2015)10 | Randomized not blinded clinical trial | 30 | Lumbar spinal stenosis | 2 | 67.9 ± 8.6 | 56.3 | SKT 7.5 g/d | 16 | 87.50% | 6.25% |
| 2 | 66.7 ± 9.5 | 50 | Eperisone | 14 | 28.57% | 0% |
Treatment data for study participants. Summary of literature included in the systematic review.
Abbreviations: GJG, Goshajinkigan; SKT, Shakuyaku‐kanzo‐to.